AEON Biopharma, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2024. AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA), a botulinum toxin complex. Following a strategic pivot in July 2024, the company is pursuing a Section 351(k) biosimilar regulatory pathway for ABP-450 using AbbVie's Botox as the reference product, rather than an original Biologics License Application (BLA) for specific therapeutic indications. The company completed a merger with Priveterra Acquisition Corp. in July 2023 and trades on the NYSE American under the symbol "AEON."
Key Financial Metrics
| Metric | 2024 (Successor) | 2023 (Successor Period) | 2023 (Predecessor Period) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income (Loss) | $42.0 million | ($324.0 million) | ($60.7 million) |
| Operating Income (Loss) | $73.0 million | ($318.4 million) | ($29.6 million) |
| Cash and Cash Equivalents (Dec 31, 2024) | $13,000 | $5.2 million | N/A |
| Accumulated Deficit (Dec 31, 2024) | ($431.6 million) | ($473.6 million) | N/A |
| Convertible Notes (Fair Value) | $11.7 million | $0 | N/A |
Note: The 2024 net income is primarily driven by a non-cash gain of $100.8 million related to the change in fair value of contingent consideration. The company has no product revenue.
Material Changes and Operational Updates
- Strategic Pivot: In May 2024, the company discontinued Phase 2 clinical trials for episodic and chronic migraine after failing to meet primary endpoints. In July 2024, it reprioritized to pursue a biosimilar pathway for ABP-450 against Botox.
- Financing Activities:
- Issued $15.0 million in senior secured convertible notes to Daewoong Pharmaceutical Co., Ltd. in March and April 2024.
- Completed a public offering in January 2025 (subsequent to year-end) raising approximately $18.3 million in net proceeds.
- Capital Structure: Implemented a 1-for-72 reverse stock split effective February 26, 2025, reducing outstanding shares from approximately 79.9 million to 1.1 million.
- Cost Reduction: SG&A expenses decreased by 31% compared to the prior year due to reduced legal fees and workforce reductions following the strategic pivot.
Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash was only $13,000. The company expects to have sufficient cash to fund operations into the fourth quarter of 2025 based on the January 2025 offering proceeds but will require additional financing.
- Listing Compliance: The company received a notice of non-compliance from NYSE American regarding stockholders' equity requirements. It has 18 months to submit and execute a compliance plan to avoid delisting.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to the valuation of complex financial instruments and lack of segregation of duties.
- Legal Proceedings: Ongoing litigation with Odeon Capital Group LLC regarding a deferred underwriting fee of $1.25 million; summary judgment motions were filed in March 2025.
- Third-Party Reliance: The company relies exclusively on Daewoong for the manufacturing and supply of ABP-450. Termination of this agreement could halt operations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $18.3 million raised in January 2025 to fund the biosimilar development plan through Q4 2025 and the timeline for any subsequent capital raises.
- Regulatory Pathway: Confirm the FDA's feedback on the proposed 351(k) biosimilar pathway for ABP-450, specifically regarding the feasibility of using Botox as a reference product for therapeutic indications.
- Listing Status: Monitor the company's progress in meeting NYSE American's stockholders' equity requirements to avoid delisting.
- Daewoong Agreement: Review the terms of the license and supply agreement, specifically the "Termination Purchase Right" which allows Daewoong to acquire AEON's know-how for $1.00 if commercialization or clinical studies cease for six months.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting and internal controls.